{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:38:23Z","timestamp":1787002703814,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41366-025-01883-6","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T14:28:35Z","timestamp":1755268115000},"page":"2131-2139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between overweight and obesity determined by body mass index and overall survival in patients with metastatic prostate cancer: a meta-analysis"],"prefix":"10.1038","volume":"49","author":[{"given":"Feilun","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfeng","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-5031","authenticated-orcid":false,"given":"Yongjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4095-8427","authenticated-orcid":false,"given":"Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"1883_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"1883_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378:645\u201357.","journal-title":"N Engl J Med"},{"key":"1883_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020;69:1473\u201380.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1883_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221103988","volume":"14","author":"MW Farha","year":"2022","unstructured":"Farha MW, Salami SS. Biomarkers for prostate cancer detection and risk stratification. Ther Adv Urol. 2022;14:17562872221103988.","journal-title":"Ther Adv Urol"},{"key":"1883_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103543","volume":"169","author":"RL Wilson","year":"2022","unstructured":"Wilson RL, Taaffe DR, Newton RU, Hart NH, Lyons-Wall P, Galv\u00e3o DA. Obesity and prostate cancer: A narrative review. Crit Rev Oncol Hematol. 2022;169:103543.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1883_CR6","first-page":"1478","volume":"110","author":"S Halabi","year":"2007","unstructured":"Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer Med. 2007;110:1478\u201384.","journal-title":"Cancer Med"},{"key":"1883_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41391-021-00418-0","volume":"25","author":"A Martini","year":"2022","unstructured":"Martini A, Shah QN, Waingankar N, Sfakianos JP, Tsao CK, Necchi A, et al. The obesity paradox in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:472\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1883_CR8","volume":"31","author":"S Verma","year":"2022","unstructured":"Verma S, Arora S, Sahoo RK, Singh P, Nayak B, Haresh KP, et al. Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer - An exploratory analysis. Cancer Treat Res Commun. 2022;31:100520.","journal-title":"Cancer Treat Res Commun"},{"key":"1883_CR9","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.juro.2007.07.026","volume":"178","author":"RB Montgomery","year":"2007","unstructured":"Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, et al. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol. 2007;178:1946\u201351.","journal-title":"J Urol"},{"key":"1883_CR10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/pros.24369","volume":"82","author":"AK Morgans","year":"2022","unstructured":"Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, et al. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Prostate. 2022;82:1176\u201385.","journal-title":"Prostate"},{"key":"1883_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/pcan.2008.36","volume":"12","author":"AJ Armstrong","year":"2009","unstructured":"Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2009;12:88\u201393.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1883_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.601513","volume":"11","author":"LW Chang","year":"2021","unstructured":"Chang LW, Hung SC, Li JR, Chiu KY, Yang CK, Chen CS, et al. Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. Front Pharmacol. 2021;11:601513.","journal-title":"Front Pharmacol"},{"key":"1883_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139. W264.","journal-title":"Ann Intern Med"},{"key":"1883_CR14","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (accessed February 19, 2025)."},{"key":"1883_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","journal-title":"Biometrics"},{"key":"1883_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"1883_CR17","doi-asserted-by":"publisher","first-page":"e0122047","DOI":"10.1371\/journal.pone.0122047","volume":"10","author":"W Wu","year":"2015","unstructured":"Wu W, Liu X, Chaftari P, Cruz Carreras MT, Gonzalez C, Viets-Upchurch J, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. PLoS One. 2015;10:e0122047.","journal-title":"PLoS One"},{"key":"1883_CR18","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.clnesp.2016.04.001","volume":"13","author":"SJ Cushen","year":"2016","unstructured":"Cushen SJ, Power DG, Murphy KP, McDermott R, Griffin BT, Lim M, et al. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr ESPEN. 2016;13:e39\u2013e45.","journal-title":"Clin Nutr ESPEN"},{"key":"1883_CR19","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.1002\/cam4.4205","volume":"10","author":"J Pan","year":"2021","unstructured":"Pan J, Wang J, Wei Y, Zhang T, Zhang S, Ye D, et al. Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials. Cancer Med. 2021;10:6697\u2013704.","journal-title":"Cancer Med"},{"key":"1883_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/pros.24403","volume":"82","author":"D Modonutti","year":"2022","unstructured":"Modonutti D, Majdalany SE, Corsi N, Li P, Sood A, Dalela D, et al. A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis. Prostate. 2022;82:1293\u2013303.","journal-title":"Prostate"},{"key":"1883_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/pros.24644","volume":"84","author":"S Govindan","year":"2024","unstructured":"Govindan S, Cheranda N, Riekhof F, Luo S, Schoen MW. Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Prostate. 2024;84:245\u201353.","journal-title":"Prostate"},{"key":"1883_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.5534\/wjmh.230155","volume":"42","author":"TS Chen","year":"2024","unstructured":"Chen TS, Liu HY, Chang YL, Chuang YC, Chen YT, Su YL, et al. Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis. World J Mens Health. 2024;42:630\u20137.","journal-title":"World J Mens Health"},{"key":"1883_CR23","doi-asserted-by":"publisher","first-page":"e213520","DOI":"10.1001\/jamanetworkopen.2021.3520","volume":"4","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, et al. Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4:e213520.","journal-title":"JAMA Netw Open"},{"key":"1883_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.advnut.2024.100282","volume":"15","author":"T Takaoka","year":"2024","unstructured":"Takaoka T, Yaegashi A, Watanabe D. Prevalence of and Survival with Cachexia among Patients with Cancer: A Systematic Review and Meta-Analysis. Adv Nutr. 2024;15:100282.","journal-title":"Adv Nutr"},{"key":"1883_CR25","first-page":"176","volume":"77","author":"FG Ramadani","year":"2024","unstructured":"Ramadani FG, Perdana NR, Ringoringo DRL. Body mass index, obesity and risk of prostate cancer: a systematic review and meta-analysis. Cent European J Urol. 2024;77:176\u201388.","journal-title":"Cent European J Urol"},{"key":"1883_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/iju.13473","volume":"25","author":"K Mitsuzuka","year":"2018","unstructured":"Mitsuzuka K, Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol. 2018;25:45\u201353.","journal-title":"Int J Urol"},{"key":"1883_CR27","doi-asserted-by":"publisher","first-page":"12137","DOI":"10.3390\/ijms252212137","volume":"25","author":"KT Liermann-Wooldrik","year":"2024","unstructured":"Liermann-Wooldrik KT, Kosmacek EA, Oberley-Deegan RE. Adipose tissues have been overlooked as players in prostate cancer progression. Int J Mol Sci. 2024;25:12137.","journal-title":"Int J Mol Sci"},{"key":"1883_CR28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1517\/14728222.2015.1035710","volume":"19","author":"A Katira","year":"2015","unstructured":"Katira A, Tan PH. Adiponectin and its receptor signaling: an anti-cancer therapeutic target and its implications for anti-tumor immunity. Expert Opin Ther Targets. 2015;19:1105\u201325.","journal-title":"Expert Opin Ther Targets"},{"key":"1883_CR29","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1158\/1055-9965.EPI-14-0699-T","volume":"23","author":"CM Kitahara","year":"2014","unstructured":"Kitahara CM, Trabert B, Katki HA, Chaturvedi AK, Kemp TJ, Pinto LA, et al. Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance. Cancer Epidemiol Biomarkers Prev. 2014;23:2840\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1883_CR30","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/14712598.2022.2108701","volume":"22","author":"E Chandran","year":"2022","unstructured":"Chandran E, Meininger L, Karzai F, Madan RA. Signaling new therapeutic opportunities: cytokines in prostate cancer. Expert Opin Biol Ther. 2022;22:1233\u201343.","journal-title":"Expert Opin Biol Ther"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01883-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:16:46Z","timestamp":1762165006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01883-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1038\/s41366-025-01883-6","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}